Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
Subscribe To Our Newsletter & Stay Updated
